CPNP News
President's Message
Dear Colleagues,
2008 is upon us- Happy belated New Year to you all. The CPNP Board has been busy planning for the year ahead. In fact we just completed a 3-day strategic planning retreat in Kansas City (and you all thought we'd be soaking in some sun rays in south Florida). Of note, we spent a good portion of the retreat, along with a few other CPNP leaders, discussing and planning for the development of a CPNP Research and Education foundation. The foundation would extend efforts to support CPNP member research, education and training. We also identified a number of CPNP initiatives for the coming year, many of which will be addressed through our committees and task forces. Some of the initiatives address member services and products, residency training, educational standards for psychiatric pharmacy in schools of pharmacy, and outreach with frontline pharmacists serving the mentally ill. Look forward to the details being discussed at the Annual Meeting in Scottsdale Arizona, this April.
As you all know, the Communications Committee, Board and CPNP staff have been working very hard on the website redesign. This project is near completion as is the updated CPNP logo. We expect this to be launched in February or early March, so be on the lookout for our new look. Lastly, I would like to thank each of you who volunteered to serve on a committee in 2008-2009. We again had a record high number of volunteers. President-elect Carla Cobb and the rest of the board are working diligently to assign each of you to a committee that will benefit most from the unique talents and experiences you have to offer CPNP.
Our organization by many standards is small, but we have the opportunity to make a great difference, one member at a time!
Sheila Botts, CPNP President
What New Resources are Available at www.cpnp.org?
- Check out the summary of the recent meeting of the National Advisory Mental Health Council
- Information and registration for the 2008 recertification products is available along with updates on the new BPS requirements related to recertification.
-
CPNP Annual Meeting Updates
- Early registration and the Scottsdale Plaza room block expires March 14. Register soon!
- CME credit will be available in 2008. Alert your physician, nurse practitioner and healthcare colleagues of this outstanding educational opportunity.
- Industry Symposia are being confirmed over the next few weeks. Be aware that many will have their own registration requirements.
- Poster submissions have ceased and acceptance notices are anticipated to be delivered via email the first week in February. A record 132 submissions were received.
What's New at NAMI
If you have never pulled up the NAMI website, or if it has been awhile since you have seen it, go back and take a look! Some recent additions to the NAMI website include:
- Veterans Resource Center: links to information about PTSD and Traumatic Brain Injury, how to access VA services, discussion groups, and a link to the NAMI Veterans Council
- NAMI Walks: Updated information on places, dates, and registration information nationwide
- NAMI National Convention: Scheduled for June 13-16, 2008 in Orlando, Florida.
- News: Front page story about a possible association between depression and type 2 diabetes mellitus
- Presidential Candidate Positions on Mental Health Issues
CPNP Member Happenings
New Jobs/Promotions
M. Lynn Crismon, PharmD, BCPP was appointed dean of The University of Texas at Austin College of Pharmacy.
Deanna Kelly, PharmD, BCPP was appointed Acting Chief and Director of the Maryland Psychiatric Research Center Treatment Research Program at the University of Maryland School of Medicine.
Julie Kissack, PharmD, BCPP was appointed Chair of the Department of Pharmacy Practice at Harding University in Arkansas. She started the position in January 2008.
Awards/ Grants/ Publications
Charles F. Caley, PharmD, BCPP will be giving a presentation about providing psychiatric pharmacy services in a university student health services system at the upcoming annual meeting of the American College Health Association in June.
Angel Elliott, PharmD, BCPP, CGP was awarded the 2007 Preceptor of the Year from Campbell University
Deanna Kelly, PharmD, BCPP became the Project Manager/PI of a 5 year Residential Research Contract with the National Institutes of Drug Abuse (NIDA). In addition, Dr. Kelly was inducted as a full member into the American College of Neuropsychopharmacogy (ACNP).
Karen Moeller, PharmD, BCPP, Kelly Lee, PharmD., BCPP and Julie Kissack, PharmD., BCPP recently published “Urine drug screening: practical guide for clinicians.†in the Mayo Clinic Proceedings 2008 Jan;83(1):66-76.
Births
Sara Dugan, PharmD, BCPP and husband are happy to announce the birth of their second child, Hannah Marie Dugan born on Friday, January 4th at 10:14 am weighing 8lb 3 oz and was 19.25 inches long.
Talia Puzantian, PharmD, BCPP, husband Bruce are happy to announce the birth of their second son Oliver Jack Atkinson, born on June 11, 2007. Son Henry (4.5 years old) is a proud Big Brother.
Depression and Antidepressants
Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
Arch Gen Psychiatry 2008; 65: 94-101. Olfson M, et al. Abstract
Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
NEJM 2008;358 (3):252-260. Turner EH, et al. Abstract
Dementia
Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease
Neurology 2008;70 299-303. Ransmayr GN, et al. Abstract
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Neurology 2008;70 17-24. Szekely CA, et al. Abstract
Psychosis and Antipsychotics
Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.
Lancet 2008;371:57-63. Tyrer P, Olover-Africano PC, et. al. Abstract
Comparison of Intramuscular Ziprasidone, Olanzapine, or Aripiprazole for Agitation: A Quantitative Review of Efficacy and Safety.
J Clin Psych 2007;68(12):1876-1884. Citrome L. Abstract
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Psychopharmacology 2007;195:285–295 Suzuki T, H Uchida, et al. Abstract
Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Trial
JAMA 2008;299(2):185-193. Ren-Rong W, et al. Abstract
Risk of Hospitalization for Acute Pancreatitis Associated with Conventional and Atypical Antipsychotics: A Population-Based Case-Control Study
Pharmacotherapy 2008 28(1):27-34. Gasse C. et al. Abstract
Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia Schizophrenia Research 2008 (98)(1-3):8-15. Mullins D. et al. Abstract
Neurology
Incidence and Prognosis of Transient Neurological Attacks
JAMA 2007;298(24):2877-2885. Bos MJ et al. Abstract
Clinical trial outcome in neuropathic pain: Relationship to study characteristics
Neurology 2008;70 263-272. Jennifer Katz J, et al. Abstract
Sleep Disorders
Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin An American Academy of Sleep Medicine Report
Sleep 2007 30(12):1705-1711. Morgenthaler TI. Et al. Abstract
Treatment of Narcolepsy and other Hypersomnias of Central Origin An American Academy of Sleep Medicine Review
Sleep 2007 30(12):1712-1727. Wise MS et al. Abstract
News
F.D.A. Requiring Suicide Studies in Drug Trials. News Article
Pharmacists Believe Drive-Through Windows Contribute to Errors. News Article
Pfizer's Chantix Gets Warning Over Suicidal Thoughts. News Article, Press Release
Keppra XRTM Extended- Release Tablets Filed with the FDA. News Article
FDA Outside Experts to Review Long-Lasting Version of Lilly's Schizophrenia Drug Zyprexa. News Article
Smoking linked with risk of suicide: study. News Article
AstraZeneca Submits sNDAs for Seroquel XRâ„¢ for the Treatment of Bipolar Mania and Bipolar Depression. Press Release